UVA-1 Promising for Patients With Refractory Alopecia Areata

This article originally appeared here.
Share this content:
UVA-1 Promising for Patients With Refractory Alopecia Areata
UVA-1 Promising for Patients With Refractory Alopecia Areata

MONDAY, Sept. 28, 2015 (HealthDay News) -- For patients with alopecia areata (AA), phototherapy with ultraviolet A-1 (UVA-1) is a promising treatment modality, according to a research letter published in the October issue of the International Journal of Dermatology.

Maira E. Herz-Ruelas, M.D., from the University Hospital in Monterrey, Mexico, and colleagues treated four patients with refractory AA with UVA-1 phototherapy. Before and after 75 sessions, the authors obtained two 4 mm punch scalp biopsies from the margin of an alopecic plaque.

At baseline, the researchers identified moderate to prominent peribulbar lymphocytic inflammation, high percentage of telogen hairs, low percentage of anagen hairs, decreased anagen/telogen ratio, and hair follicle miniaturization. After 75 sessions, in all four patients there was a prominent reduction of inflammatory infiltrate, a reduction in telogen hairs and hair follicle miniaturization with an increase in anagen hairs, and an absence of telogen remnants. Three patients achieved a severity of alopecia tool (SALT) score of S0; the patient with the most severe alopecia (initial SALT S3) obtained an S1 score with hair regrowth. Improvement was sustained for six months after treatment.

"To the best of our knowledge, this is an initial report of hair regrowth with this phototherapy," the authors write. "We feel that UVA-1 could be included as a therapeutic alternative for patients unresponsive to previous topical or systemic pharmacological treatments."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »